Ontology highlight
ABSTRACT:
SUBMITTER: Hou J
PROVIDER: S-EPMC5500972 | biostudies-literature | 2017 Jul
REPOSITORIES: biostudies-literature
Hou Jian J Jin Jie J Xu Yan Y Wu Depei D Ke Xiaoyan X Zhou Daobin D Lu Jin J Du Xin X Chen Xiequn X Li Junmin J Liu Jing J Gupta Neeraj N Hanley Michael J MJ Li Hongmei H Hua Zhaowei Z Wang Bingxia B Zhang Xiaoquan X Wang Hui H van de Velde Helgi H Richardson Paul G PG Moreau Philippe P
Journal of hematology & oncology 20170706 1
<h4>Background</h4>The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide-dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies.<h4>Methods</h4>Patients were randomized (1:1) to receive ixazomib 4.0 mg or placebo on days 1, 8, and 15, plus lenalidomide 25 mg on days 1-21 and dexamethasone 40 mg on days 1, ...[more]